Tenderwize
Wróć do wyszukiwania

Open house drug rebate agreements Lanthanum(III)-carbonate, ATC V03AE03

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline May 03, 2028 · 614 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lanthan(III)-carbonat, ATC V03AE03

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

20 / 100

Czynniki ryzyka

No estimated value or guaranteed volume; revenue depends on actual usage and discount rates

Automatic termination if a competing nationwide or state-level rebate contract is concluded for the same active substan...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2028
  • Non-exclusive pharmaceutical rebate agreements for Lanthanum(III)-carbonate (ATC V03AE03)
  • Supply of pharmaceutical products to AOK Bayern at discounted prices
Pokaż pełne podsumowanie

Non-exclusive open-house model for pharmaceutical rebate agreements on Lanthanum(III) carbonate (ATC V03AE03) with AOK Bayern. Eligible pharmaceutical companies can join at any time until 03 May 2028, with contracts running from 01 July 2026 to 30 June 2028. No estimated value provided. Submission is either in writing (two copies) or electronically with qualified electronic signature. Only self-declaration of reliability is required for eligibility. The contract is non-negotiable and non-exclusive.

Ryzyka

No estimated value or guaranteed volume; revenue depends on actual usage and discount rates

Automatic termination if a competing nationwide or state-level rebate contract is concluded for the same active substan...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible

Administrative

  • Submission of signed self-declaration of reliability
  • Submission of signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel'

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria – all eligible companies are accepted.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open house drug rebate agreements Lanthanum(III)-carbonate, ATC V03AE03

Open-house model for non-exclusive rebate agreements on pharmaceutical products containing Lanthanum(III)-carbonate (ATC V03AE03). Contracts available to all interested pharmaceutical companies meeting eligibility criteria. No selection process; all eligible companies can join. Duration from 01 July 2026 to 30 June 2028. Submission deadlines for joining: 3rd of each month for next month start, or later. Contracts may be terminated with one month's notice.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Jun 2026 - Jun 2028

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria – all eligible companies are accepted.

Termin

Deadline May 03, 2028

Szczegóły zamówienia

Data publikacji
17 May 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
337536-2026

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30